Disease · MONDO_0021678

gram-negative bacterial infections

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gram-negative bacterial infections. Diseases, record MONDO_0021678. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021678

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gram-negative bacterial infections; Open Targets
Open Targets ID: MONDO_0021678; Open Targets
MeSH: D016905; MeSH
Highest stage of its drugs: Approval, for 8 of its 16 drugs, from ClinicalTrials.gov and EMA Human Drugs; Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AVIBACTAM	CHEMBL1689063	Small molecule	Approval	EMA Human Drugs	6	4	4	Drugs and targets
AZTREONAM	CHEMBL158	Small molecule	Approval	EMA Human Drugs	3	2	2	Drugs and targets
CEFTAZIDIME	CHEMBL44354	Small molecule	Approval	EMA Human Drugs	3	2	2	Drugs and targets
IMIPENEM	CHEMBL43708	Small molecule	Approval	EMA Human Drugs	3	2	2	Drugs and targets
RELEBACTAM	CHEMBL3301605	Small molecule	Approval	EMA Human Drugs	3	2	2	Drugs and targets
CEFIDEROCOL	CHEMBL3989974	Small molecule	Approval	ClinicalTrials.gov and EMA Human Drugs	2	1	1	Drugs and targets
CILASTATIN	CHEMBL766	Small molecule	Approval	EMA Human Drugs	2	1	1	Drugs and targets
ERTAPENEM	CHEMBL1359	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets
FOSFOMYCIN	CHEMBL1757	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METRONIDAZOLE	CHEMBL137	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
DPEP1	Dipeptidase 1	1	Renal dipeptidase inhibitor	Approval	https://conductscience.org/library/genes/1800

Source Drugs and targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03969901	Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)	Phase 2/3	115	2025-05-13	Suspected or Documented Gram-negative Bacterial Infection	IMIPENEM, RELEBACTAM	Open Targets' reading of its record	ClinicalTrials.gov
NCT03230916	A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)	Phase 1	47	2021-12-13	Suspected or Documented Gram-negative Bacterial Infection	CILASTATIN, IMIPENEM, RELEBACTAM	Its record names the disease	ClinicalTrials.gov
NCT04358991	Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF		20	2020-05-15	Bacterial Infections	AVIBACTAM, CEFTAZIDIME	Its record names the disease	ClinicalTrials.gov
NCT06990126	The Efficacy and Adverse Reactions of Neotetracycline in the Treatment of GNB Infections		300		Clinical Efficacy and Safety	ERAVACYCLINE, TIGECYCLINE	Its record names the disease	ClinicalTrials.gov
NCT07063095	A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections	Phase 3	100		Gram Negative Infections, Sepsis and Septic Shock	AVIBACTAM, CEFTAZIDIME, FOSFOMYCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT05639647	Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections	Phase 2	48		Gram-negative Bacterial Infections	AVIBACTAM, AZTREONAM, METRONIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT06462235	A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)	Phase 2	48		Gram-negative Bacterial Infection	AVIBACTAM, AZTREONAM, METRONIDAZOLE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03780140	Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections				Bacterial Infections	CEFIDEROCOL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37562063	RESULT	1	PubMed
42400209	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021678

GET https://conductscience.org/api/diseases/v1/MONDO_0021678/drugs

API reference For AI assistants